These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29416370)

  • 21. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged-release oxycodone/naloxone in opioid-naïve patients - subgroup analysis of a prospective observational study.
    Hesselbarth S; Hermanns K; Oepen P
    Expert Opin Pharmacother; 2015 Mar; 16(4):457-64. PubMed ID: 25612469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial.
    Lee KH; Kim TW; Kang JH; Kim JS; Ahn JS; Kim SY; Yun HJ; Eum YJ; Koh SA; Kim MK; Hong YS; Kim JE; Lee GW
    Chin J Cancer; 2017 Sep; 36(1):74. PubMed ID: 28893309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.
    Ahmedzai SH; Leppert W; Janecki M; Pakosz A; Lomax M; Duerr H; Hopp M
    Support Care Cancer; 2015 Mar; 23(3):823-30. PubMed ID: 25218610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis.
    Roberto A; Greco MT; Legramandi L; Galli F; Galli M; Corli O
    J Pain Res; 2017; 10():2123-2133. PubMed ID: 28919810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
    Leppert W
    Adv Ther; 2010 Oct; 27(10):714-30. PubMed ID: 20799006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.
    Ueberall MA; Mueller-Schwefe GH
    J Pain Res; 2015; 8():459-75. PubMed ID: 26300655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
    Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
    Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients.
    Guerriero F; Sgarlata C; Marcassa C; Ricevuti G; Rollone M
    Clin Interv Aging; 2015; 10():1-11. PubMed ID: 25565782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Itopride increases the effectiveness of the management of opioid-induced constipation in palliative care patients: an observational non-interventional study.
    Dzierżanowski T; Kozlowski M
    Arch Med Sci; 2022; 18(5):1271-1278. PubMed ID: 36160363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
    Clemens KE; Quednau I; Klaschik E
    Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
    van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
    Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice.
    Kuusniemi K; Zöllner J; Sjövall S; Huhtala J; Karjalainen P; Kokki M; Lemken J; Oppermann J; Kokki H
    J Int Med Res; 2012; 40(5):1775-93. PubMed ID: 23206459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study.
    Cuomo A; Russo G; Esposito G; Forte CA; Connola M; Marcassa C
    Am J Hosp Palliat Care; 2014 Dec; 31(8):867-76. PubMed ID: 24249829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence.
    DePriest AZ; Miller K
    Pain Ther; 2014 Jun; 3(1):1-15. PubMed ID: 25135384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Severe Pain and Opioid-induced Constipation: An Observational Study of Quality of Life, Resource Use, and Costs in Sweden.
    Hjalte F; Ragnarson Tennvall G; Welin KO; Westerling D
    Pain Ther; 2016 Dec; 5(2):227-236. PubMed ID: 27830531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and economical evaluation of new analgesics for the management of chronic pain].
    Coluzzi F; Ruggeri M
    Recenti Prog Med; 2014 Nov; 105(11):415-9. PubMed ID: 25424235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis.
    Lazzari M; Sabato AF; Caldarulo C; Casali M; Gafforio P; Marcassa C; Leonardis F
    Curr Med Res Opin; 2014 Apr; 30(4):555-64. PubMed ID: 24251879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.